Study of Oral PQR309 in Patients With Advanced Solid Tumors

Summary

This is an open-label, multi-center, non-randomized, dose escalation Phase 1 study evaluating safety, tolerability, PK (pharmacokinetics) and efficacy of PQR309 in the treatment of selected patients with advanced solid tumors.

Conditions

• Cancer

Interventions

DRUG

PQR 309

Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy

Sponsors & Collaborators

• Roswell Park Cancer Institute

  collaborator OTHER

• M.D. Anderson Cancer Center

  collaborator OTHER

• Mayo Clinic

  collaborator OTHER

• Hospital Clinic of Barcelona

  collaborator OTHER

• University College London Hospitals

  collaborator OTHER

• Churchill Hospital

  collaborator OTHER

• Case Western Reserve University

  collaborator OTHER

• University Hospital, Zürich

  collaborator OTHER

• PIQUR Therapeutics AG

  lead INDUSTRY

Principal Investigators

• Mateusz Opyrchal · Roswell Park Cancer Institute

• Filip Janku · MD Anderson Cancer

• Afshin Dowlati · University Hospitals Cleveland Medical Center

• Alex Adjei · Mayo Clinic

• Jordi Rodon · Vall d'Hebron University Hospital

• Martin Forster · University College London Hospitals

• Sarah Bladgen · Chruchill Hospital

• Andreas Wicki · Basel University Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-03-21

Primary Completion

2019-03-21

Completion

2019-03-21

FDA Drug

Yes

Countries

• United States

Study Locations